Myristoylcarnitine

metabolite

Acylcarnitine accumulation reflects impaired mitochondrial fatty-acid oxidation and energy crisis in ischemic myocardium.

Pathway placement

Cascade stepLipid retention & oxidation

Confidencemedium

RationaleAcylcarnitine from fatty acid β-oxidation; elevated in ischemic cardiomyocyte injury.

Also acts inMyocardial injury

Druggability

Not assessed (no mapped human gene target).

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.

Specimen

Serum, plasma or urine

Collection tube

Serum separator (gold/red-top, SST) · Lithium heparin (green-top) · Sterile urine container

Method / principle

LC-MS/MS (targeted metabolomics) or enzymatic colorimetric where available

Reagent / substrate

Stable-isotope-labeled internal standard (MS); or enzyme-coupled Trinder reagent

Platform

LC-MS/MS; some automated chemistry

Turnaround · availability

Send-out / research · Specialized / research